<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab5">
 <label>Table 5</label>
 <caption>
  <p>US FDA-approved human mAbs</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>No.</th>
    <th>Antibody</th>
    <th>Brandname</th>
    <th>Company</th>
    <th>Approval
     <sup>#</sup>
    </th>
    <th>Target</th>
    <th>References</th>
    <th>Technology</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1</td>
    <td>Adalimumab</td>
    <td>Humira</td>
    <td>Abbott_Laboratories</td>
    <td>2002</td>
    <td>TNFα</td>
    <td>den Broeder et al. [
     <xref ref-type="bibr" rid="CR178">178</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>2</td>
    <td>Panitumumab</td>
    <td>Vectibix</td>
    <td>Amgen</td>
    <td>2006</td>
    <td>EGFR</td>
    <td>Tyagi et al. [
     <xref ref-type="bibr" rid="CR179">179</xref>]
    </td>
    <td>XenoMouse</td>
   </tr>
   <tr>
    <td>3</td>
    <td>Ustekinumab</td>
    <td>Stelara</td>
    <td>Johnson &amp; Johnson</td>
    <td>2009</td>
    <td>IL-12</td>
    <td>Bartlett et al. [
     <xref ref-type="bibr" rid="CR17">17</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>4</td>
    <td>Canakinumab</td>
    <td>Ilaris</td>
    <td>Novartis</td>
    <td>2009</td>
    <td>IL-1β</td>
    <td>Church et al. [
     <xref ref-type="bibr" rid="CR18">18</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>5</td>
    <td>Golimumab</td>
    <td>Simponi</td>
    <td>Johnson &amp; Johnson/Merck</td>
    <td>2009</td>
    <td>TNFα</td>
    <td>Zhou et al. [
     <xref ref-type="bibr" rid="CR19">19</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>6</td>
    <td>Ofatumumab</td>
    <td>Arzerra</td>
    <td>GlaxoSmithKline (Genmab)</td>
    <td>2009</td>
    <td>CD20</td>
    <td>Coiffier et al. [
     <xref ref-type="bibr" rid="CR20">20</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>7</td>
    <td>Denosumab</td>
    <td>Prolia, Xgeva</td>
    <td>Amgen</td>
    <td>2010</td>
    <td>RANKL</td>
    <td>Reddy et al. [
     <xref ref-type="bibr" rid="CR21">21</xref>]
    </td>
    <td>XenoMouse</td>
   </tr>
   <tr>
    <td>8</td>
    <td>Belimumab</td>
    <td>Benlysta</td>
    <td>GlaxoSmithKline</td>
    <td>2011</td>
    <td>BCAF</td>
    <td>Ding et al. [
     <xref ref-type="bibr" rid="CR180">180</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>9</td>
    <td>Ipilimumab</td>
    <td>Yervoy</td>
    <td>Bristol-Myers Squibb</td>
    <td>2011</td>
    <td>CTLA-4</td>
    <td>Morse et al. [
     <xref ref-type="bibr" rid="CR22">22</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>10</td>
    <td>Ramucirumab</td>
    <td>Cyramza</td>
    <td>Eli Lilly (ImClone)</td>
    <td>2014</td>
    <td>VEGFR2</td>
    <td>Krupitskaya et al. [
     <xref ref-type="bibr" rid="CR181">181</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>11</td>
    <td>Nivolumab</td>
    <td>Opdivo</td>
    <td>Bristol-Myers Squibb</td>
    <td>2014</td>
    <td>PD-1</td>
    <td>Wolchok et al. [
     <xref ref-type="bibr" rid="CR23">23</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>12</td>
    <td>Alirocumab</td>
    <td>Praluent</td>
    <td>Sanofi and Regeneron</td>
    <td>2015</td>
    <td>PCSK9</td>
    <td>Roth et al. [
     <xref ref-type="bibr" rid="CR24">24</xref>]
    </td>
    <td>Veloclmmune Mouse</td>
   </tr>
   <tr>
    <td>13</td>
    <td>Daratumumab</td>
    <td>Darzalex</td>
    <td>Johnson &amp; Johnson (Genmab)</td>
    <td>2015</td>
    <td>CD38</td>
    <td>de Weers et al. [
     <xref ref-type="bibr" rid="CR25">25</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>14</td>
    <td>Necitumumab</td>
    <td>Portrazza</td>
    <td>Eli Lilly (ImClone)</td>
    <td>2015</td>
    <td>EGFR</td>
    <td>Kuenen et al. [
     <xref ref-type="bibr" rid="CR182">182</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>15</td>
    <td>Evolocumab</td>
    <td>Repatha</td>
    <td>Amgen</td>
    <td>2015</td>
    <td>PCSK9</td>
    <td>Hirayama et al. [
     <xref ref-type="bibr" rid="CR26">26</xref>]
    </td>
    <td>XenoMouse</td>
   </tr>
   <tr>
    <td>16</td>
    <td>Secukinumab</td>
    <td>Cosentyx</td>
    <td>Novartis</td>
    <td>2015</td>
    <td>IL-17α</td>
    <td>Chioato et al. [
     <xref ref-type="bibr" rid="CR27">27</xref>]
    </td>
    <td>XenoMouse</td>
   </tr>
   <tr>
    <td>17</td>
    <td>Olaratumab</td>
    <td>Lartruvo</td>
    <td>Eli Lilly</td>
    <td>2016</td>
    <td>PDGFRα</td>
    <td>Chiorean et al. [
     <xref ref-type="bibr" rid="CR28">28</xref>]
    </td>
    <td>HuMabMouse</td>
   </tr>
   <tr>
    <td>18</td>
    <td>Atezolizumab</td>
    <td>Tecentriq</td>
    <td>Roche</td>
    <td>2016</td>
    <td>PD-L1</td>
    <td>McDermott et al. [
     <xref ref-type="bibr" rid="CR183">183</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>19</td>
    <td>Avelumab</td>
    <td>Bavencio</td>
    <td>Pfizer</td>
    <td>2017</td>
    <td>PD-L1</td>
    <td>Boyerinas et al. [
     <xref ref-type="bibr" rid="CR184">184</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>20</td>
    <td>Brodalumab</td>
    <td>Siliq</td>
    <td>Valeant Pharmaceuticals</td>
    <td>2017</td>
    <td>IL-17R</td>
    <td>Papp et al. [
     <xref ref-type="bibr" rid="CR29">29</xref>]
    </td>
    <td>XenoMouse</td>
   </tr>
   <tr>
    <td>21</td>
    <td>Dupilumab</td>
    <td>Dupixent</td>
    <td>Sanofi and Regeneron</td>
    <td>2017</td>
    <td>IL-4R</td>
    <td>Wenzel et al. [
     <xref ref-type="bibr" rid="CR30">30</xref>]
    </td>
    <td>Veloclmmune Mouse</td>
   </tr>
   <tr>
    <td>22</td>
    <td>Durvalumab</td>
    <td>Imfinzi</td>
    <td>Medimmune/AstraZeneca</td>
    <td>2017</td>
    <td>PD-L1</td>
    <td>Antonia et al. [
     <xref ref-type="bibr" rid="CR31">31</xref>]
    </td>
    <td>XenoMouse</td>
   </tr>
   <tr>
    <td>23</td>
    <td>Guselkumab</td>
    <td>Tremfya</td>
    <td>Jassen Biotech</td>
    <td>2017</td>
    <td>IL-23</td>
    <td>Sofen et al. [
     <xref ref-type="bibr" rid="CR185">185</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>24</td>
    <td>Sarilumab</td>
    <td>Kevzara</td>
    <td>Sanofi and Regeneron</td>
    <td>2017</td>
    <td>IL-6R</td>
    <td>Huizinga et al. [
     <xref ref-type="bibr" rid="CR32">32</xref>]
    </td>
    <td>Veloclmmune Mouse</td>
   </tr>
   <tr>
    <td>25</td>
    <td>Erenumab</td>
    <td>Aimovig</td>
    <td>Novartis and Amgen</td>
    <td>2018</td>
    <td>CGRPR</td>
    <td>Tepper et al. [
     <xref ref-type="bibr" rid="CR33">33</xref>]
    </td>
    <td>XenoMouse</td>
   </tr>
   <tr>
    <td>26</td>
    <td>Cemiplimab</td>
    <td>Libtayo</td>
    <td>Regeneron</td>
    <td>2018</td>
    <td>PD-1</td>
    <td>Migden et al. [
     <xref ref-type="bibr" rid="CR34">34</xref>]
    </td>
    <td>Veloclmmune Mouse</td>
   </tr>
   <tr>
    <td>27</td>
    <td>Emapalumab</td>
    <td>Gamifant</td>
    <td>NovImmmune</td>
    <td>2018</td>
    <td>IFNγ</td>
    <td>Al-Salama ZT [
     <xref ref-type="bibr" rid="CR186">186</xref>]
    </td>
    <td>Phage display</td>
   </tr>
   <tr>
    <td>28</td>
    <td>Moxetumomab pasudodox</td>
    <td>Lumoxiti</td>
    <td>MedImmune/AstraZeneca</td>
    <td>2018</td>
    <td>CD22</td>
    <td>Kreitman et al. [
     <xref ref-type="bibr" rid="CR187">187</xref>]
    </td>
    <td>Phage display</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <sup>#</sup>Year of the first US FDA approval
  </p>
 </table-wrap-foot>
</table-wrap>
